Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

For all those peo­ple who could nev­er quite be­lieve that Amarin $AM­RN would get an ex­pand­ed la­bel with block­buster im­pli­ca­tions, the stress and anx­i­ety …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.